Tag:
GlycoVaxyn
Latest Headlines
Latest Headlines
Live From BIO: Vaccines in the 21st century
CHICAGO - With new pathogens coming to the fore, new vaccines are absolutely still necessary, an expert panel said Tuesday at the BIO 2010 convention. But while opportunities exist, so do a number of
GlycoVaxyn banks $22M in second round
The Swiss vaccine developer GlycoVaxyn has ginned $22 million for its Series B round. Edmond de Rothschild Investment Partners led the round with Index Ventures and Sofinnova Partners joining in.
GlycoVaxyn banks $22 million in second round
The Swiss vaccine developer GlycoVaxyn has ginned $22 million for its Series B round. Edmond de Rothschild Investment Partners led the round with Index Ventures and Sofinnova Partners joining in.
